Bone Biologics Corporation · NASDAQ (us_market)
· · United States
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-02-25$35.95 RISE2026-05-21$14.15 PEAK2026-05-29$17.93 93d | -60.6% 85d | Missed | Missed | — | — | +26.7% 8d | Missed |
DROP2026-02-25$35.95 RISE2026-05-20$14.15 PEAK2026-05-29$17.93 93d | -60.6% 84d | Missed | Missed | — | — | +26.7% 9d | Missed |
DROP2026-02-25$35.95 RISE2026-04-09$13.01 PEAK2026-04-15$20.00 49d | -63.8% 43d | Missed | Missed | — | — | +53.7% 6d | Missed |
DROP2026-02-25$35.95 RISE2026-04-08$13.01 PEAK2026-04-15$20.00 49d | -63.8% 42d | Missed | Missed | — | — | +53.7% 7d | Missed |
DROP2025-12-22$22.00 RISE2026-02-04$11.40 PEAK2026-02-23$35.95 63d | -48.2% 44d | Missed | Missed | — | — | +215.4% 19d | Missed |
DROP2025-12-22$22.00 RISE2026-02-03$11.40 PEAK2026-02-23$35.95 63d | -48.2% 43d | Missed | Missed | — | — | +215.4% 20d | Missed |
DROP2025-08-11$15.00 RISE2025-10-29$10.39 PEAK2025-12-17$22.00 128d | -30.7% 79d | Missed | Missed | — | — | +111.7% 49d | Missed |
DROP2025-08-11$15.00 RISE2025-10-28$10.39 PEAK2025-12-17$22.00 128d | -30.7% 78d | Missed | Missed | — | — | +111.7% 50d | Missed |
DROP2025-08-11$15.00 RISE2025-10-27$10.39 PEAK2025-12-17$22.00 128d | -30.7% 77d | Missed | Missed | — | — | +111.7% 51d | Missed |
DROP2025-08-11$15.00 RISE2025-10-24$10.39 PEAK2025-12-17$22.00 128d | -30.7% 74d | Missed | Missed | — | — | +111.7% 54d | Missed |
DROP2025-08-11$15.00 RISE2025-10-23$10.39 PEAK2025-12-17$22.00 128d | -30.7% 73d | Missed | Missed | — | — | +111.7% 55d | Missed |
DROP2025-08-11$15.00 RISE2025-10-22$10.39 PEAK2025-12-17$22.00 128d | -30.7% 72d | Missed | Missed | — | — | +111.7% 56d | Missed |
DROP2025-08-11$15.00 RISE2025-10-21$10.39 PEAK2025-12-17$22.00 128d | -30.7% 71d | Missed | Missed | — | — | +111.7% 57d | Missed |
DROP2025-08-11$15.00 RISE2025-10-20$10.39 PEAK2025-12-17$22.00 128d | -30.7% 70d | Missed | Missed | — | — | +111.7% 58d | Missed |
DROP2025-08-11$15.00 RISE2025-10-17$10.39 PEAK2025-12-17$22.00 128d | -30.7% 67d | Missed | Missed | — | — | +111.7% 61d | Missed |
1–15 / 97 1 / 7 | |||||||
No scored news yet for a sentiment trend.
By Brad Sorensen, CFA NASDAQ:BBLG READ THE FULL BBLG RESEARCH REPORT Bone Biologics (NASDAQ:BBLG) is a clinical-stage biotechnology company focused on transforming the multibillion-dollar spine fusion and bone regeneration market through its proprietary orthobiologic technology. At the heart of its platform is a novel recombinant human protein known as NELL-1 , which the company has exclusively
td class="col-issue">Next Technology Holding Inc.
td class="col-issue">Next Technology Holding Inc.
BURLINGTON, Mass., September 04, 2025--Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that President and Chief Executive Officer Jeffrey Frelick has issued the following letter to stockholders.
BURLINGTON, Mass., September 03, 2025--Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that Jeffrey Frelick, President and Chief Executive Officer, will participate in the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025.
By Brad Sorensen, CFA NASDAQ:BBLG READ THE FULL BBLG RESEARCH REPORT Bone Biologics (NASDAQ:BBLG) is a company developing products for spine fusion market and is entering an exciting and crucial time period as human trials have begun and results should be available, at least preliminary data, in the coming year. Given the preclinical studies that we’ve reported on extensively, we are optimistic
BURLINGTON, Mass., June 30, 2025--Bone Biologics Corporation ("Bone Biologics" or the "Company") (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously announced public offering of an aggregate of 1,250,000 shares of its common stock (or common stock equivalents in lieu thereof), Series D warrants to purchase up to 1,250,000 shares of common stock and Series E short-term warrants to purchase up to 1,250,000 shares of c
BURLINGTON, Mass., June 27, 2025--Bone Biologics Corporation ("Bone Biologics" or the "Company") (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced the pricing of its public offering of an aggregate of 1,250,000 shares of its common stock (or common stock equivalents in lieu thereof), Series D warrants to purchase up to 1,250,000 shares of common stock and Series E short-term warrants to purchase up to 1,250,000 shares of common stock, at a pub
By Brad Sorensen, CFA NASDAQ:BBLG READ THE FULL BBLG RESEARCH REPORT Bone Biologics (NASDAQ:BBLG) is a company developing products for the spine fusion market and is entering an exciting and crucial time period as human trials have begun and results should be available, at least preliminary data, in the coming year. Given the preclinical studies that we’ve reported on extensively, we are
BURLINGTON, Mass., June 27, 2025--Bone Biologics files U.S. patent application for bone regeneration technology
Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, today announced the pricing of its public offering of an aggregate of
BURLINGTON, Mass., June 26, 2025--Bone Biologics Corporation ("Bone Biologics" or the "Company") (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule") for continued listing on the Nasdaq Capital Market. Bone Biologics is now in complian
By Brad Sorensen, CFA NASDAQ:BBLG READ THE FULL BBLG RESEARCH REPORT Bone Biologics (NASDAQ:BBLG) is a company developing products for spine fusion market and is entering an exciting and crucial time period as human trials have begun and results should be available, at least preliminary data, in the coming year. Given the preclinical studies that we’ve reported on extensively, we are optimistic
BURLINGTON, Mass., June 06, 2025--Bone Biologics Corporation ("Bone Biologics" or the "Company") (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced a planned reverse stock split of its shares of common stock at a ratio of 1-for-6. The reverse stock split will take effect as of 12:01 a.m. ET, on Tuesday, June 10, 2025, and shares of Bone Biologics are expected to trade on a post-split basis on Nasdaq under the existing trading symbol, "BBLG," at